The prospective, open-label, randomized clinical trial included 200 patients (mean age, 69 years; 71% men) with AF or atrial flutter with a history of AF from five hospitals in the US, Canada, and Australia. All were current coffee drinkers or had been regular coffee drinkers in the past 5 years and had planned an electrical cardioversion.
Clinically detected recurrence of AF or atrial flutter over 6 months served as the primary outcome measure.
The researchers randomly assigned patients 1:1 to caffeinated coffee consumption or coffee abstinence. Patients in both arms had a baseline coffee intake of seven cups per week.
During follow-up, coffee intake in the consumption arm was seven cups per week compared with none in the abstinence group.
Results indicated a decrease in AF or atrial flutter recurrence in the coffee-consumption group compared with the coffee-abstinence group (47% vs 64%; hazard ratio [HR], 0.61; 95% CI, 0.42-0.89). Researchers also observed a similar benefit of coffee consumption for AF recurrence only (HR, 0.62; 95% CI, 0.43-0.91), but not for flutter recurrence only, which occurred in just 6% of the study population (HR, 0.37; 95% CI, 0.10-1.41).
Adverse events did not differ between groups.
https://www.medscape.com/viewarticle/can-coffee-cut-risk-atrial-fibrillation-2025a1000w11
RU
EN